Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| In Silico-Based Structural Evaluation to Categorize the Pathogenicity of Mutations Identified in the RAD Class of Proteins. | ACS Omega | 2023 | 36969410 | PubTator, text mining | PubMed |
| Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib. | Front Oncol | 2023 | 36969051 | PubTator, text mining | PubMed |
| Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases. | Front Oncol | 2023 | 36969007 | PubTator, text mining | PubMed |
| Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration. | NPJ Precis Oncol | 2023 | 36964191 | PubTator, text mining | PubMed |
| Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO. | Gynecol Oncol Rep | 2023 | 36938343 | PubTator, text mining | PubMed |
| Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. | J Ovarian Res | 2023 | 36922847 | PubTator, text mining | PubMed |
| Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma. | Nat Commun | 2023 | 36922497 | PubTator, text mining | PubMed |
| Prevalence of germline mutations in cancer susceptibility genes in Chinese patients with renal cell carcinoma. | Transl Androl Urol | 2023 | 36915884 | PubTator, text mining | PubMed |
| Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. | Neurooncol Adv | 2023 | 36915613 | PubTator, text mining | PubMed |
| A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. | NPJ Precis Oncol | 2023 | 36914848 | PubTator, text mining | PubMed |
| PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality. | Front Oncol | 2023 | 36910637 | PubTator, text mining | PubMed |
| Hereditary cancer syndromes. | World J Clin Oncol | 2023 | 36908677 | PubTator, text mining | PubMed |
| Breast Cancer and Genetic BRCA1/2 Testing in Routine Clinical Practice: Why, When and For Whom? | Geburtshilfe Frauenheilkd | 2023 | 36908286 | PubTator, text mining | PubMed |
| Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress. | Nat Commun | 2023 | 36906610 | PubTator, text mining | PubMed |
| Variant curation and interpretation in hereditary cancer genes: An institutional experience in Latin America. | Mol Genet Genomic Med | 2023 | 36905130 | PubTator, text mining | PubMed |
| DNA Damage and Its Role in Cancer Therapeutics. | Int J Mol Sci | 2023 | 36902170 | PubTator, text mining | PubMed |
| Aberrations of DNA Repair Pathways in Prostate Cancer-The State of the Art. | Int J Mol Sci | 2023 | 36901732 | PubTator, text mining | PubMed |
| Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. | Cancers (Basel) | 2023 | 36900375 | PubTator, text mining | PubMed |
| Characterization of BRCA Deficiency in Ovarian Cancer. | Cancers (Basel) | 2023 | 36900320 | PubTator, text mining | PubMed |
| Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer. | J Natl Compr Canc Netw | 2023 | 36898365 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=31